How to Read a Biotech 10-K: The Sections That Actually Matter

The Most Complete Source You're Not Reading

The Form 10-K is a company's comprehensive annual report to the SEC: audited financials, a full business description, and an exhaustive list of risks. For a biotech, it's the single most complete primary source for due diligence — and most retail investors never open it. Reading it efficiently means knowing which sections carry signal.

Section by Section

Business (Item 1). The pipeline overview. Read how the company describes each program's stage, mechanism of action, and target indication. Note what it emphasizes — and what it downplays or omits compared to last year's 10-K.

Risk Factors (Item 1A). Often dismissed as boilerplate, but changes year-over-year are revealing. A newly added risk factor — about a specific trial, a manufacturing issue, a financing need, or a competitive threat — is the company telling you, in legally careful language, what it's worried about. Compare this year's risks to last year's.

MD&A (Item 7). Management's Discussion and Analysis is where the financials are explained. For biotech, zero in on:

• Liquidity and capital resources — how much cash, the burn rate, and management's own statement about how long the cash lasts.
• R&D expense — rising spend can mean an advancing pipeline; check it against trial activity.
• Any discussion of financing plans or an ATM program.

Financial Statements and Footnotes (Item 8). The footnotes are where the real story often hides:

• Going concern language — a serious flag (covered below).
• Commitments and contingencies — milestone obligations, royalty deals, litigation.
• Share count and equity — the basis for assessing dilution.

What to Triangulate

A 10-K is most powerful when cross-checked against other sources:

1. Pipeline claims vs. ClinicalTrials.gov. Does the 10-K's description of trial progress match the registry's status and dates?
2. Cash and runway vs. the catalyst calendar. Does the company have enough cash to reach its next major readout or PDUFA date without raising?
3. This year's risk factors vs. last year's. New or expanded risks point to where management's concerns are growing.
4. R&D trends vs. pipeline narrative. A pipeline described as "advancing" while R&D spend falls is worth questioning.

Red Flags to Watch

• Going concern doubt in the audit opinion or footnotes.
• A risk factor that newly emphasizes a single pivotal trial the company depends on.
• Heavy near-term milestone or royalty obligations that will consume cash.
• A growing accumulated deficit with no clear path to revenue and a short runway.
• Frequent or large subsequent-event disclosures about financings.

The 10-K and the Catalyst Picture

The 10-K is an annual snapshot; pair it with the 10-Q for quarterly updates and the 8-K for material events between reports. Together they let you track how the financial and pipeline story evolves in real time, rather than once a year.

Applying It

You don't have to read a 10-K cover to cover. Start with Risk Factors (and compare to last year), the liquidity discussion in MD&A, and the going-concern and commitments footnotes. Those sections tell you most of what determines biotech risk: how long the cash lasts, what management fears, and what obligations loom.

Then connect it to the catalysts. Review the company's pipeline and financials on its company page, estimate its runway with the cash runway tool, and line up its filings against the events on the catalyst calendar. The 10-K is dense, but the parts that matter to a biotech thesis are a small, knowable subset.